Highlights of This Issue 2193

SPECIAL FEATURES

CCR 20th Anniversary Commentary

2195 CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio
Susan E. Bates, Robert W. Robey, and Richard L. Piekaz

2198 CCR 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy
Wm. Kevin Kelly, Paul Marks, and Victoria M. Richon

CCR Translations

2201 A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
Yanping Xiao and Gordon J. Freeman
See related article, p. 2359

2204 Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String"
Lisa M. Rimsza
See related article, p. 2367

Molecular Pathways

2207 Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells
Hiba Ahmad Zahreddine and Katherine L.B. Borden

CCR Focus

2212 Quit Early, Quit Often
Susan E. Bates

2213 Lung Cancer in the Era of Precision Medicine
Katerina Politi and Roy S. Herbst

2221 EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
Gregory J. Riely and Helena A. Yu

2227 Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Ryohei Katayama, Christine M. Lovly, and Alice T. Shaw

2236 Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
David R. Gandara, Peter S. Hammertime, Martin L. Sos
Primo N. Lara Jr, and Fred R. Hirsch

2244 Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
M. Catherine Pietanza, Lauren Averett Byers, John D. Minna, and Charles M. Rudin

2256 Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
Jean-Charles Soria, Aurelien Marabelle, Julie R. Brahmer, and Scott Gettinger

Special Report

2263 Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care
Edward Abrahams, Margaret Foti, and Marcia A. Kean

CANCER THERAPY: CLINICAL

2268 Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer

2278 Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
ABOUT THE COVER

The cover shows a section of a bone marrow biopsy from a patient with acute myeloid leukemia (AML). Immunohistochemical staining shows Desert Hedgehog positive osteoblasts underlining the hypothesis of paracrine Hedgehog pathway activation in AML cells. For details, see the article by Wellbrock and colleagues on page 2388 of this issue.